共 50 条
Maintenance immunosuppression in myasthenia gravis, an update
被引:41
作者:
Morren, John
[1
]
Li, Yuebing
[1
]
机构:
[1] Cleveland Clin, Neurol Inst, Neuromuscular Ctr, 9500 Euclid Ave S90, Cleveland, OH 44195 USA
关键词:
Myasthenia gravis;
Immunosuppression;
Corticosteroid;
Non-steroid immunosuppressive agent;
Intravenous immunoglobulin;
Plasmapheresis;
Thymectomy;
LONG-TERM TREATMENT;
PRIMARY CNS LYMPHOMA;
OCULAR MYASTHENIA;
MYCOPHENOLATE-MOFETIL;
DOUBLE-BLIND;
INTRAVENOUS IMMUNOGLOBULIN;
ACETYLCHOLINE-RECEPTOR;
CORTICOSTEROID TREATMENT;
TREATMENT STRATEGY;
CLINICAL FINDINGS;
D O I:
10.1016/j.jns.2019.116648
中图分类号:
R74 [神经病学与精神病学];
学科分类号:
摘要:
Therapies for myasthenia gravis (MG) include symptomatic and immunosuppressive/immunomodulatory treatment. Options for immunosuppression include corticosteroids, azathioprine, mycophenolate mofetil, cyclosporine, tacrolimus, methotrexate, rituximab, cyclophosphamide, eculizumab, intravenous immunoglobulin, subcutaneous immunoglobulin, plasmapheresis, and thymectomy. The practical aspects of long-term immunosuppressive therapy in MG are critically reviewed in this article. Application of one or more of these specific therapies is guided based on known efficacy, adverse effect profile, particular disease subtype and severity, and patient co-morbidities.
引用
收藏
页数:15
相关论文